Obese Participants at Risk of Cardiovascular Disease
Our lead molecule derived from our proprietary chemistry that is unlike any other NLRP3 inflammasome inhibitor in the space. NT-0796 is designed to deliver an intracellular payload directly to the specific immune cell types that drive inflammatory diseases, with potential applications in peripheral and neuroinflammatory diseases. Development of NT-0796 is now progressing in a Phase Ib/IIa study in Parkinson’s disease and Obese Participants at risk of Cardiovascular Disease NCT06129409.
NT-0249 is a brain-penetrant NLRP3 inflammasome inhibitor with excellent potency and optimized development characteristics, allowing us to develop a low-dose therapy with the potential to address chronic inflammatory diseases of the body.
Neuro Development Candidate
This CNS-penetrant compound is uniquely designed from a novel chemotype as a fully brain-penetrant NLRP3 inflammasome inhibitor, with the potential to treat a broad range of neuroinflammatory diseases.
Neuro Development Candidates